Business Wire

Nscale Acquires Kontena to Enhance HPC and AI Infrastructure Capabilities

22.7.2024 02:01:00 EEST | Business Wire | Press release

Share

Nscale, a fully vertically integrated AI cloud platform, today announced the acquisition of Kontena, a leader in high-density modular data centres and AI Data Centre solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721172829/en/

Joshua Payne, Founder and CEO, Nscale (Photo: Business Wire)

This acquisition marks a significant step forward in Nscale's mission to provide the infrastructure backbone to the growing generative AI market through cost-effective, high-performance solutions that unlock AI's full potential.

Jef Laurijssen, CEO of Kontena, commented: “Joining forces with Nscale provides us with an incredible opportunity to accelerate the development and deployment of cutting-edge Generative AI Data Centre solutions. Our combined expertise will enable us to deliver unparalleled value to our customers in the AI and HPC markets.”

Capitalising on Kontena’s innovative KONNECT ecosystem combined with Nscale’s extensive infrastructure capabilities, the two companies will deliver high-performance solutions. Kontena's flagship product, the EDGE data room, is a fully modular Generative AI Data Centre solution designed to meet the complex demands of advancing AI development. The EDGE data room is one of the world’s first modular solution deploying AI infrastructure on-premises and in remote locations, far quicker and at lower cost than traditional Tier 3 Data Centres.

Nscale’s acquisition of Kontena bolsters its commitment to sustainability. Kontena’s modular AI data centre solutions will enable Nscale to deliver faster and more cost-effective deployments for customers at its 100% renewable data centre sites in Norway and the US.

Joshua Payne, CEO of Nscale, commented: “The acquisition of Kontena allows Nscale to design, build, and deploy bespoke GPU clusters at scale for global Generative AI customers more quickly and more cost-effectively than the competition. Building Kontena into the Nscale value chain will allow us to deliver bespoke GPU superclusters and data centre builds for our large supercluster and hyperscale customers across Nscale’s 500MW of greenfield data centre capacity. This modular system can be deployed in Nscale’s data centres, on-premise, or at the edge to deliver unrivalled speed, performance, and efficiency on GenAI workloads. This is an important step towards our goal of vertical integration.”

This acquisition underscores Nscale’s dedication to driving innovation and delivering exceptional value to its customers. It follows Nscale’s recent announcement of a strategic partnership with Open Innovation AI, a leading GPU orchestration platform in MENA, targeting the deployment of 30,000 GPUs over the next 3 years, further solidifying its commitment to AI infrastructure and optimised workloads for global markets.

About Nscale

Nscale is a fully vertically integrated AI GPU Cloud provider delivering compute to the generative AI market at scale. Leveraging its 60MW renewable energy-powered data centre in Norway and a pipeline of over 500MW of greenfield data centres in the US. Nscale enables customers to run efficient and scalable AI training, fine-tuning, and compute-intensive workloads, supporting advanced AI research and development. Nscale provides the AI infrastructure backbone to the generative AI market.

About Kontena

Founded in 2018, Kontena specialises in high-density data centres and HPC solutions, combining innovation with practicality. The company recently collaborated with ElioVP and Bluesio to develop better and more innovative AI and HPC solutions.

For more information about Nscale’s AI & HPC solutions and the Kontena acquisition, visit nscale.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240721172829/en/

Contacts

Media contact
The Hoffman Agency for Nscale
NscaleEU@hoffman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye